Ultragenyx Pharmaceutical Inc. (RARE)
Ultragenyx Pharmaceutical Inc. (RARE) from its SEC filings: 2025 revenue $673.0 million (+20% vs the year before), net margin -85%, free cash flow -$472.0 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $673.0 million |
| Revenue growth | +20% |
| Net income | -$575.0 million |
| Net margin | -85.4% |
| Free cash flow | -$472.0 million |
| Diluted EPS | $-5.83 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +28% |
| Cash | $125.0 million |
| Share count, 1 year | +2% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.